Traders Buy Large Volume of Call Options on TransMedics Group (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) was the recipient of unusually large options trading activity on Monday. Stock traders acquired 3,274 call options on the stock. This represents an increase of approximately 262% compared to the average volume of 904 call options.

Insider Buying and Selling

In related news, Director James R. Tobin sold 20,000 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the sale, the director now owns 173,146 shares in the company, valued at $27,587,352.18. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James R. Tobin sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the sale, the director now owns 173,146 shares in the company, valued at $27,587,352.18. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,205 shares of company stock worth $9,981,907 over the last quarter. 7.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC purchased a new stake in TransMedics Group in the 2nd quarter worth approximately $47,000. USA Financial Formulas purchased a new stake in TransMedics Group in the 3rd quarter worth approximately $55,000. J.Safra Asset Management Corp raised its holdings in shares of TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares in the last quarter. Signaturefd LLC raised its holdings in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares in the last quarter. Finally, Fidelis Capital Partners LLC bought a new position in shares of TransMedics Group during the 1st quarter valued at $35,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Up 1.9 %

Shares of NASDAQ:TMDX traded up $2.43 during mid-day trading on Monday, hitting $127.60. The stock had a trading volume of 1,502,540 shares, compared to its average volume of 847,477. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The company has a market cap of $4.26 billion, a PE ratio of 3,325.25 and a beta of 1.99. TransMedics Group has a 12-month low of $36.42 and a 12-month high of $177.37. The company’s 50 day moving average is $148.39 and its 200-day moving average is $139.96.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm’s quarterly revenue was up 117.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.03) EPS. On average, sell-side analysts predict that TransMedics Group will post 1.22 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on TMDX. Oppenheimer raised their price target on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Stephens increased their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective on shares of TransMedics Group in a report on Monday, October 7th. Finally, Morgan Stanley increased their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, TransMedics Group currently has an average rating of “Buy” and a consensus target price of $174.30.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.